Christopher P. Cannon – författare

Dyslipidemia affects almost half of American adults and is the most prevalent manageable risk factor for atherosclerosis. Lipid disorders often co-occur with other prevalent conditions such as diabetes and kidney disease; they are also often a concern with certain medication regimens (such as anti-retroviral and certain anti-psychotic agents). Proper treatment of dyslipidemia can reduce the risk of peripheral arterial disease, revascularization procedures, nonfatal myocardial infarction, stroke, and cardiac death. However, only 20% of adults meet the national guidelines for cholesterol control.As part of the Oxford American Cardiology Library, this practical handbook is designed to serve as a concise yet authoritative resource on diagnosing and treating dyslipidemia. The book is tailored to the needs of busy health care professionals treating patients in various clinical settings, and focuses on presenting essential information to clinicians who are at the forefront of the diagnosis and management of dyslipidemia. Featuring evidence-based, concise yet comprehensive discussion of key clinical concepts in addition to numerous figures, tables and illustrations, this pocket-sized handbook will serve as an invaluable guide to healthcare professionals.

The first atlas devoted specifically to cardiometabolic risk, this book will provide a concise visual primer on the pathophysiology, epidemiology, diagnosis, treatment, and clinical and radiologic features of this disorder.  Describing recent care strategies and current practices in patient assessment, this source will allow clinicians to accurately identify and treat those patients at increased risk for metabolic syndrome, cardiovascular disease, and diabetes.

Acute coronary syndrome (ACS) continues to challenge our health care system in the complexity of presentation and the ever increasing number of patients exhibiting signs and symptoms of an acute coronary syndrome.

In this second edition of his highly acclaimed book, Christopher P. Cannon, MD, and a team of preeminent clinical investigators have thoroughly revised and expanded every chapter to reflect the recent explosion of clinical trials on the management of acute coronary syndromes (ACS). This includes: the newer tests, such as C reactive protein; a multimarker approach to diagnosis and risk stratification; new antiplatelet agents; and combinations of thrombolytic antithrombotic regimens. Also discussed are the latest developments in interventional cardiology, the use of cost-effectiveness in clinical trials to choose appropriate therapies, and the employment of critical pathways analysis to improve compliance with evidence-based medicine and guideline recommendations.

In this second edition of his highly acclaimed book, Christopher P. Cannon, MD, and a team of preeminent clinical investigators have thoroughly revised and expanded every chapter to reflect the recent explosion of clinical trials on the management of acute coronary syndromes (ACS). This includes: the newer tests, such as C reactive protein; a multimarker approach to diagnosis and risk stratification; new antiplatelet agents; and combinations of thrombolytic-antithrombotic regimens. Also discussed are the latest developments in interventional cardiology, the use of cost-effectiveness in clinical trials to choose appropriate therapies, and the employment of critical pathways analysis to improve compliance with evidence-based medicine and guideline recommendations.

Comprehensive Cardiovascular Medicine in the Primary Care Setting provides an authoritative, detailed discussion of cardiovascular disease balanced with practical utility.

The thoroughly updated second edition of this key textbook provides an authoritative discussion of cardiovascular disease for the practicing primary care clinician.